California State Teachers Retirement System Purchases 13,963,607 Shares of Medpace Holdings, Inc. $MEDP

California State Teachers Retirement System grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 53,619.6% in the second quarter, HoldingsChannel.com reports. The fund owned 13,989,649 shares of the company’s stock after acquiring an additional 13,963,607 shares during the quarter. California State Teachers Retirement System owned 0.50% of Medpace worth $7,408,778,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in MEDP. Johnson Financial Group Inc. acquired a new position in Medpace in the second quarter valued at approximately $27,000. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Elyxium Wealth LLC acquired a new stake in shares of Medpace during the 4th quarter worth approximately $30,000. Jones Financial Companies Lllp bought a new stake in shares of Medpace in the 2nd quarter valued at $30,000. Finally, Allied Private Wealth LLC bought a new stake in shares of Medpace in the 2nd quarter valued at $31,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Price Performance

MEDP opened at $590.89 on Wednesday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The firm has a market capitalization of $16.49 billion, a PE ratio of 34.64, a P/E/G ratio of 2.64 and a beta of 1.15. The company’s 50-day moving average is $577.04 and its 200 day moving average is $502.19.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter last year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $535.00 target price on shares of Medpace in a research note on Thursday, July 23rd. BMO Capital Markets lifted their price target on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Mizuho upped their price objective on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and raised their target price for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Finally, Barclays set a $600.00 target price on Medpace in a research report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $595.20.

Insider Buying and Selling

In related news, CEO August J. Troendle sold 650 shares of the company’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $620.27, for a total transaction of $403,175.50. Following the completion of the sale, the chief executive officer owned 539,894 shares in the company, valued at approximately $334,880,051.38. This represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Brian T. Carley sold 5,000 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total value of $3,043,150.00. Following the sale, the director owned 27,825 shares of the company’s stock, valued at $16,935,129.75. This trade represents a 15.23% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 134,471 shares of company stock valued at $82,151,311. 20.50% of the stock is owned by company insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.